Skin Cancer in Dogs (Cutaneous Adenocarcinoma)
- Occurrence: rarer
- Location of disease: Skin/Fur
When to visit the vet?
Non-urgent see a veterinarian within 2–3 days
If the condition worsens / symptoms persist, consult a veterinarian.
Definition
Cutaneous adenocarcinoma is a malignant tumor that arises from the glandular structures of the skin. These malignant neoplasms can originate from various gland types, including sebaceous, sweat, or apocrine glands. Unlike benign adenomas, adenocarcinomas exhibit an invasive growth pattern and the potential to metastasize. Histologically, these tumors are characterized by atypical glandular cells that disrupt the normal tissue architecture and can infiltrate the surrounding tissue.
Das Wichtigste auf einen Blick
Cutaneous adenocarcinoma in dogs is a malignant tumor that arises from the glandular structures of the skin and accounts for approximately 2–6% of all cutaneous neoplasms. These tumors occur predominantly in older dogs and show a certain breed predisposition. The etiology is multifactorial, with genetic factors, environmental influences, and chronic inflammatory processes playing a role.
Clinically, adenocarcinomas present as progressively growing, firm nodules that can ulcerate in advanced stages. Diagnosis is made through a combination of clinical examination, cytological and histopathological examination, and imaging procedures for staging.
The therapy of choice is wide surgical excision with tumor-free resection margins. In cases of incomplete resection or high-grade malignant tumors, adjuvant therapies such as radiation therapy or, in selected cases, chemotherapy may be indicated. Newer therapeutic approaches such as electrochemotherapy, targeted therapies, and immunotherapeutic procedures expand the therapeutic spectrum.
The prognosis depends significantly on the tumor stage, histological grade, and completeness of surgical resection. Structured follow-up care with regular clinical examinations and imaging studies is essential to detect recurrence or metastases early.
The early detection of Skin changes by the owner and prompt veterinary clarification are crucial for an optimal treatment outcome. Owners should therefore be instructed to perform regular skin examinations on their dog and have changes clarified by a veterinarian immediately.
Ursachen
Cutaneous adenocarcinomas account for approximately 2–6% of all cutaneous neoplasms in dogs and are among the rarer skin tumors. They occur predominantly in older dogs, with the average age of onset around 10–12 years. Certain breeds such as Cocker Spaniels, Poodles, and Labrador Retrievers appear to have a certain predisposition, suggesting genetic factors. The biological significance of these tumors lies in their locally aggressive behavior and ability to metastasize to lymph nodes and distant organs, making them a serious oncological condition.
The etiology of cutaneous adenocarcinomas is multifactorial and not fully understood. Scientific evidence suggests an interplay of various factors:
Genetic predispositions play an important role, as evidenced by the increased occurrence in certain dog breeds. Molecular genetic studies have identified specific genetic alterations, including mutations in tumor suppressor genes and oncogenes, which can contribute to the malignant transformation of glandular cells.
Environmental factors such as chronic UV exposure can contribute to carcinogenesis, particularly in thinly haired or unpigmented skin areas. Long-term exposure to chemical carcinogens in the environment is also discussed as a possible risk factor.
A particularly important pathogenetic mechanism is the connection between chronic inflammatory processes and tumor development. Persistent skin inflammation can impair DNA repair mechanisms and promote malignant transformation through continuous tissue damage, oxidative stress, and the release of inflammatory mediators. This explains why non-healing skin inflammation can pose an increased risk for the development of adenocarcinomas.
Hormonal factors are also discussed as possible influencing factors, especially for tumors arising from hormone-dependent glandular structures. However, the evidence for this is less clear in cutaneous adenocarcinoma than in other tumor types.
Symptoms
The clinical presentation of cutaneous adenocarcinomas can vary but shows characteristic features that may be recognizable to pet owners. Typically, these tumors manifest as solitary, firm nodules in the skin or subcutaneous tissue. The size can range from a few millimeters to several centimeters, with larger tumors often having an irregular surface.
A significant clinical feature is the growth behavior: adenocarcinomas often show progressive growth over weeks to months. In advanced stages, the tumors can ulcerate, leading to bleeding, secretion, and secondary bacterial infections. These complications manifest through oozing, unpleasant odor, and pain at the affected site.
Affected dogs often show increased licking or scratching at the tumor site, indicating local itching or discomfort. In tumors in mechanically stressed areas such as the paws or joint regions, lameness or movement restrictions may occur.
In advanced disease with metastasis, systemic symptoms may occur, including lethargy, inappetence, weight loss, and, depending on the location of metastases, organ-specific symptoms. Enlarged regional lymph nodes may indicate lymphogenic metastasis and should always be carefully palpated.
Particularly problematic are adenocarcinomas that develop from chronic, non-healing inflammatory foci. Here, the transition from chronic dermatitis to a malignant process can be difficult for the owner to recognize, which underscores the importance of regular veterinary examinations for persistent skin changes.
Diagnose
- Biopsy of the lesion for histopathological examination.
- Imaging procedures such as ultrasound, X-ray, or CT to assess spread.
The diagnosis of cutaneous adenocarcinoma requires a systematic approach that combines clinical, cytological, histopathological, and imaging procedures. The diagnostic algorithm begins with a thorough clinical examination, in which the size, consistency, mobility, and demarcation of the tumor as well as the condition of the regional lymph nodes are assessed.
Cytological examination by fine-needle aspiration represents an important first diagnostic step. Cells are taken from the tumor and examined microscopically. Characteristic cytological findings in adenocarcinomas are cell clusters with clear signs of cellular atypia, anisocytosis, anisokaryosis, and prominent nucleoli. Cytology can provide valuable clues but is not always sufficient for definitive diagnosis.
The gold standard for diagnosis is histopathological examination of a biopsy. This can be performed as an incisional biopsy (removal of a piece of tissue) or as an excisional biopsy (complete removal of the tumor). Histopathological examination not only enables the definitive diagnosis of an adenocarcinoma but also the determination of the histological subtype, degree of differentiation, and invasiveness, which is crucial for prognosis and treatment planning.
Modern diagnostic procedures also include immunohistochemical examinations, which can confirm the epithelial origin of the tumor through specific markers such as cytokeratins. For certain subtypes, specific markers such as estrogen or progesterone receptors can provide additional prognostic information.
Imaging procedures are essential for assessing tumor stage and ruling out metastases. These include:
- Chest X-rays in three views to rule out pulmonary metastases
- Abdominal ultrasound to assess abdominal organs and lymph nodes
- In complex cases, advanced imaging procedures such as computed tomography (CT) or magnetic resonance imaging (MRI) can be used to more precisely assess local tumor extent and detect smaller metastases
Newer diagnostic approaches such as liquid biopsy, in which circulating tumor DNA is detected in the blood, are still in the research stage in veterinary oncology but could contribute to early detection of recurrence or therapy monitoring in the future.
Therapie
Surgical removal of the tumor with a margin of healthy tissue.
Radiation therapy or chemotherapy in cases where surgical removal is not possible, or in metastatic disease.
Follow-up care for early detection of recurrence or metastases.
The therapy of cutaneous adenocarcinoma in dogs is based on a multimodal approach, with surgical intervention remaining the most important treatment option. The choice of optimal therapeutic strategy depends on the tumor stage, location, histological grade, and the patient’s general condition.
Surgical excision with wide safety margins (at least 2–3 cm laterally and one fascial layer in depth) is the first-line therapy. The goal is complete removal of the tumor with tumor-free resection margins (R0 resection), as this offers the best prognosis. In cases of unfavorable location or large tumors, reconstructive surgical procedures such as local flap plasties or free skin grafts may be necessary to close the defect.
In cases of incomplete resection (R1 or R2 resection) or high-grade malignant tumors, adjuvant radiation therapy is often recommended. Modern radiation techniques such as intensity-modulated radiation therapy (IMRT) or stereotactic radiosurgery enable precise application of the radiation dose while sparing the surrounding healthy tissue. Radiation therapy can also be considered as a primary treatment option for inoperable tumors.
Chemotherapy plays a subordinate role in the treatment of cutaneous adenocarcinoma but can be used in metastatic disease or as adjuvant therapy after incomplete resection. Commonly used chemotherapeutic agents include doxorubicin, carboplatin, and cyclophosphamide. However, response rates are variable and often not long-lasting.
Newer therapeutic approaches include:
Electrochemotherapy, in which electrical impulses increase cell membrane permeability, leads to improved intracellular uptake of chemotherapeutic agents. This method has proven particularly effective for superficial tumors.
Targeted therapies that focus on specific molecular changes in tumor cells are gaining increasing importance. Tyrosine kinase inhibitors such as toceranib have shown promising results in some cases.
Immunotherapeutic approaches, including checkpoint inhibitors that activate the body’s own immune system to fight tumor cells, are currently being investigated in clinical trials and could expand the therapeutic arsenal in the future.
When making therapeutic decisions, the animal’s age, comorbidities, expected quality of life, and the owner’s financial resources must always be considered. An open discussion between veterinarian and owner about treatment options, prospects for success, and possible side effects is appropriate for informed decision-making.
Prognose und Nachsorge
The prognosis for dogs with cutaneous adenocarcinoma is variable and depends on several factors. The most important prognostic factors include the histological grade of the tumor, the tumor stage at the time of diagnosis, the completeness of surgical resection, and the presence of metastases.
With complete surgical removal (R0 resection) of a low- to moderately malignant adenocarcinoma without metastases, the prognosis is comparatively favorable, with median survival times of 12 to 24 months. High-grade malignant tumors, incomplete resections, or the presence of metastases are associated with a significantly poorer prognosis, with median survival time dropping to 6–12 months or less.
Molecular markers such as the expression of certain growth factor receptors or the proliferation rate (Ki-67 index) can provide additional prognostic information and are increasingly being incorporated into prognosis assessment.
Follow-up care after treatment of adenocarcinoma is an essential component of the overall management and includes several components:
Regular clinical examinations are particularly important in the first two years after therapy, as the risk of local recurrence and metastases is highest during this period. Monthly examinations are recommended in the first six months, after which the intervals can be extended to three to four months.
Follow-up examinations should include a thorough clinical examination with particular attention to the surgical site and regional lymph nodes. Imaging procedures such as chest X-rays and abdominal ultrasound are performed at regular intervals (every 3-6 months) to detect metastases early.
For dogs receiving chemotherapy or targeted therapy, regular blood tests are required to monitor possible side effects and adjust dosage.
Wound care after surgical procedures is an important aspect of follow-up care. Owners should be instructed on how to recognize signs of wound healing disorders or infections and when to seek veterinary help.
Supportive measures to improve quality of life, such as adequate pain therapy, adapted nutrition, and, if necessary, physiotherapeutic measures, should be integrated into the follow-up care concept.
Prävention
For prevention of cutaneous adenocarcinoma, early detection is crucial. Regular palpation of the dog, especially in older animals, enables early detection of suspicious lumps. Wounds or skin changes that do not heal within two weeks should be examined by a veterinarian. Excessive sun exposure, especially in dogs with light skin or thin coats, should be avoided. A balanced diet and an intact immune system contribute to skin health. Since genetic factors can play a role, careful breeding selection is important. The earlier a skin tumor is detected, the greater the chances of successful treatment.
Ausblick auf aktuelle Forschung
Research in the field of canine cutaneous adenocarcinomas is continuously evolving and opening new perspectives for diagnostics and therapy. Current research priorities include molecular characterization, innovative therapeutic approaches, and improved prognostic markers.
In the field of molecular oncology, genetic and epigenetic changes in cutaneous adenocarcinomas are increasingly being identified. Through techniques such as next-generation sequencing and proteomics, specific mutations and altered signaling pathways can be characterized, representing potential targets for targeted therapies. The identification of driver mutations, similar to human adenocarcinoma, could enable the development of personalized therapeutic strategies.
A promising research area is immuno-oncology. The study of the tumor microenvironment and the interaction between tumor cells and the immune system has led to the development of new immunotherapeutic approaches. Checkpoint inhibitors, already established in human medicine, are increasingly being evaluated in veterinary studies. Initial results show promising response rates for certain tumor entities, although efficacy in cutaneous adenocarcinomas still needs further investigation.
The development of minimally invasive therapeutic procedures is another research focus. Techniques such as photodynamic therapy, in which light-activated substances selectively destroy tumor cells, or high-frequency thermal ablation are being investigated for their applicability to superficial skin tumors.
In the field of diagnostics, advances in imaging diagnostics, such as high-resolution ultrasound procedures, functional MRI techniques, or PET-CT, enable more precise tumor characterization and staging. Liquid biopsy, in which circulating tumor DNA or circulating tumor cells are detected in the blood, could in the future represent a minimally invasive method for tumor diagnostics, therapy monitoring, and recurrence detection.
Translational research approaches that transfer findings from human medicine to veterinary medicine are gaining increasing importance. Comparative oncology studies that examine similarities and differences between human and canine tumors can contribute to a better understanding of tumor biology and the development of new therapeutic approaches.
The integration of artificial intelligence and machine learning into oncological diagnostics and treatment planning represents an innovative research approach. Algorithms for automated analysis of histopathological images or for predicting response to therapy could support clinical decision-making in the future.